- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03638440
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. (NACASY)
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With Opioid Induced Constipation.
Study Overview
Detailed Description
The objective of this study is to assess the safety and efficacy of Naloxegol in a real world setting in cancer patients.
The primary safety end point is the incidence of adverse events leading to study discontinuation.
The primary efficacy end point is the response rate assessed in the 4 week observation period. Response is defined as three or more bowel movements (without the use of rescue laxative treatment in the previous 24 hours) per week and an increase of one or more bowel movements over baseline.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aalborg, Denmark
- Aalborg University Hospital
-
-
-
-
-
Tampere, Finland
- Tampere University Hospital
-
-
-
-
-
Nantes, France
- Paul Papin à Angers et site René Gauducheau
-
-
-
-
-
Lübeck, Germany
- Lubecker Onkologische
-
-
-
-
-
Athens, Greece
- Areteion Hospital
-
-
-
-
-
Napoli, Italy
- Aorn Dei Colli
-
-
-
-
-
Arnhem, Netherlands
- Rijnstate Hospital
-
-
-
-
-
Barcelona, Spain
- ICO-Hospitalet
-
-
-
-
-
Lund, Sweden
- Skåne University Hospital
-
-
-
-
Surrey
-
Guildford, Surrey, United Kingdom
- Royal Surrey County Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient ≥ 18 years old
- Patient who is receiving treatment with opioids for at least 4 weeks, and is expected to remain on opioids for duration of study
- Patient with opioid-induced constipation
- Patient in whom the clinician plans treatment with Naloxegol according to routine clinical practice (Naloxegol SmPC recommends that all currently used maintenance laxative therapy should be halted)
- Signing of the informed consent
Exclusion Criteria:
- Patients with colorectal cancer
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the safety and efficacy of Naloxegol in a real world setting in cancer patients.
Time Frame: 4 week treatment period
|
Response rate
|
4 week treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients that have a BFI score change of ≥12 points at the end of the study treatment
Time Frame: 4 week observation period
|
Bowel Function Index (BFI) score change of ≥12 points
|
4 week observation period
|
Proportion of patients that have a BFI score <30 at the end of the study (patients adequately treated).
Time Frame: 4 week observation period
|
Bowel Function Index (BFI) score <30
|
4 week observation period
|
Time to the first post-dose bowel movement
Time Frame: 4 week observation period
|
Time to first post-dose bowel movement
|
4 week observation period
|
Change in stool consistency
Time Frame: 4 week observation period
|
Bristol stool scale (BSS)
|
4 week observation period
|
Change in Patient Assessment of Constipation (PAC-QOL)
Time Frame: 4 week observation period
|
Quality of Life Questionnaire
|
4 week observation period
|
Incidence of overall adverse events, including SAEs
Time Frame: 4 week observation period
|
Adverse Events, including SAEs
|
4 week observation period
|
Analgesic treatment interruptions/dose adjustments
Time Frame: 4 week observation period
|
Dose adjustments
|
4 week observation period
|
Naloxegol treatment interruptions/dose adjustments
Time Frame: 4 week observation period
|
Dose adjustments
|
4 week observation period
|
Patient satisfaction (PGI-I)
Time Frame: 4 week observation period
|
Patient Global Impression of Improvement (PGI-I)
|
4 week observation period
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jan Tack, MD, University Hospital KU Leuven
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Pain
- Neurologic Manifestations
- Signs and Symptoms, Digestive
- Narcotic-Related Disorders
- Constipation
- Opioid-Induced Constipation
- Cancer Pain
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Naloxegol
Other Study ID Numbers
- NACASY
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Induced Constipation
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center Groningen; UMC Utrecht and other collaboratorsRecruitingConstipation, Opioid-InducedNetherlands
-
Kyowa Kirin Pharmaceutical Development LtdTerminatedOpioid Induced ConstipationNetherlands, United Kingdom
-
Valinor Pharma LLCActive, not recruiting
-
Theravance BiopharmaCompletedOpioid Induced ConstipationUnited States
-
St. John Health System, MichiganUnknownOpioid-induced ConstipationUnited States
-
ShionogiRecruitingOpioid-Induced Constipation (OIC)France
-
AstraZenecaCompletedOpioid-Induced Constipation (OIC)United States, Australia, Slovakia, Germany
-
AstraZenecaCompletedOpioid-Induced Constipation (OIC)United States
-
Yeditepe University HospitalCompletedTherapeutic Opioid Induced Constipation (Disorder)
-
ShionogiCompletedOpioid-induced ConstipationUnited States, Australia, Austria, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Poland, South Africa, Spain, Sweden, United Kingdom
Clinical Trials on Naloxegol
-
Valinor Pharma LLCActive, not recruiting
-
AstraZenecaCompletedHealthy Subjects | BioavailabilityGermany
-
TriHealth Inc.Recruiting
-
Kyowa Kirin Pharmaceutical Development LtdTerminatedOpioid Induced ConstipationNetherlands, United Kingdom
-
Massachusetts General HospitalAstraZenecaTerminatedConstipationUnited States
-
Temple UniversityAstraZenecaWithdrawn
-
The Cleveland ClinicCompleted
-
Joseph MaAstraZenecaTerminated
-
Massachusetts General HospitalAstraZenecaWithdrawnCritical Illness | ConstipationUnited States
-
Michael CamilleriAstraZenecaCompletedConstipation Drug InducedUnited States